S112 • OFID 2019:6 (Suppl 2) • Poster Abstracts weeks. His endocarditis did not relapse after 6 months' treatment. (Case 2) A 71-yearold man who had a past medical history of enterococcal endocarditis was successfully treated with intravenous ampicillin and subsequent atrial valve replacement. He was admitted to our hospital because of fever and back pain. Prosthetic valve endocarditis was diagnosed because blood cultures revealed C. striatum, and evidence of metastatic lesions. While intravenous vancomycin and oral rifampin (600 mg/day) were initiated, several complications, such as pseudoaneurysm of ascending aorta, splenic artery aneurysm followed by a rupture, and cerebral hemorrhage occurred. The patient's refusal of a re-operation rendered prolonged medical treatment necessary for 16 weeks. He died 20 weeks after the diagnosis of Corynebacterium endocarditis.
Conclusion. KO and KP BSI differ in the type of host and source, suggesting different colonization dynamics. KO remains antibiotic-susceptible but might be cefazolin less susceptible. Prospective studies are needed to confirm differential cephalosporin susceptibility and delineate host-pathogen interactions.
Disclosures. All authors: No reported disclosures. Background. Bacteremia due to Pseudomonas aeruginosa is associated with high mortality and inappropriate initial antimicrobial therapy leads to worse outcomes. We aimed to analyze clinical characteristics of P. aeruginosa bacteremia and risk factors for antibiotic resistance and investigate their antimicrobial susceptibility trends.
Antimicrobial Susceptibility Trends and Risk Factors for Antibiotic
Methods. We retrospectively reviewed the medical records of patients with P. aeruginosa bacteremia admitted to a tertiary hospital between January 2009 and March 2019.
Results. A total of 242 patients were identified and the median age was 70 years [interquartile range (IQR) 57.6-75.4]. Hepatobiliary tract (28.5%) was most common primary site of infection, followed by respiratory tract (20.2%) and urinary tract (15.7%). Out of 197 (81.4%) patients treated with susceptible antibiotics and the median duration of active antibiotic therapy was 10 days (IQR 4-15.5). The percentages of susceptible P. aeruginosa to amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, colistin, gentamicin, imipenem, meropenem, piperacillin-tazobactam, and ticarcillin-clavulanate were 90.1%, 57.9%, 77.3%, 74.8%, 74.4%, 99.2%, 91.3%, 76.0%, 76.0%, 69.4%, and 51.2%. There were 24.8% carbapenem-resistant P. aeruginosa (CRPA), 36.4% multidrug-resistant P. aeruginosa (MDRPA), and 15.3% extensively drug-resistant P. aeruginosa (XDRPA). Susceptible P. aeruginosa to gentamycin and ticarcillin-clavulanate were significantly decreased in 2014-2019 than that in 2009-2013 (both; P < 0.001). Resistance rates to carbapenems and fluoroquinolones tended to increase over time. CRPA, MDRPA, and XDRPA were significantly associated with delayed active therapy (>48 h) (all; P < 0.001). Independent risk factors for CRPA were urinary tract infection (adjusted odds ratio [aOR], 3.4; 95% confidence interval [CI], 1.5-7.8), underlying hematologic malignancy (aOR, 3.0; 95% CI, 1.1-8.3) and cerebrovascular accident (aOR, 2.6; 95% CI, 1.1-5.9), hospital-acquired infection (aOR, 2.5; 95% CI, 1.0-6.1), and co-colonization with multidrug-resistant organisms (aOR, 2.2; 95% CI, 1.1-4.4).
Conclusion. The identification of risk factors for antibiotic resistance and analysis of antibiotics susceptibility are useful for early initiation of appropriate antibiotics in patients with P. aeruginosa bacteremia.
Disclosures. All authors: No reported disclosures.
Background. Up to 20% of SA isolates in the United States are penicillin-susceptible (PSSA); however, treatment with penicillin has been discouraged because of concern that routine testing may miss strains that have the capacity to produce clinically significant ß-lactamase in vivo. We performed a retrospective analysis to determine whether PCN therapy for the treatment of PSSA bacteremia was of comparable efficacy and safety to standard therapies.
Methods. We identified all episodes of SA bacteremia (March 18, 2010 -July 23, 2018 . SA penicillin susceptibility testing in our lab was performed by broth microdilution followed by nitrocefin ß-lactamase testing per CLSI guidelines on these isolates. A retrospective chart review was performed and our primary outcome was a composite endpoint of clinical success (no change in PSSA therapy due to persistent or worsening signs and symptoms, no PSSA bacteremia recurrence or persistence, and no infection-related mortality). Microbiologic failure was defined as either failure to clear bacteremia/infection or recurrence after completion of therapy. Patients were followed until last contact with our medical system, the only tertiary center in the region. We compared our rates of success, mortality, and adverse drug reaction to historical SA bacteremia controls from the literature.
Results.
PSSA accounted for 13% (130/971) of SA bloodstream episodes. Nineteen patients with PSSA (15%) were treated with PCN and 79% (15/19) achieved the primary endpoint of clinical success. Of the 4 patients who did not achieve the endpoint, 2 developed rash and were switched to a different antibiotic and 2 died from complications of sepsis. One of the patients died after clearing blood cultures but had DIC and a catastrophic intracranial hemorrhage, the other died of overwhelming sepsis after 4 days (2 days nafcillin, 2 days PCN) with continued bacteremia. Thus, our only microbiologic failure was due to early death from sepsis. Rates of success, mortality and drug reaction were similar to prior reports of alternative standard therapies (Table 1) .
Conclusion. PCN is a viable treatment option for PSSA bacteremia as identified by routine laboratory testing. Further study will include characterizing the presence of ß-lactamase in these patient's isolates.
Disclosures. All authors:
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Clinical Characterization of Staphylococcus aureus Bacteremia in Children at an Inner-City Community Hospital
Jomi K. Oommen, PharmD; Eris Cani, BS, PharmD, BCPS; Tae E. Park, PharmD; Savita Manwani, MD and Murli Purswani, MD; BronxCare Health System, New Hyde Park, New York Session: 37. Bacteremia, CLABSI, and Endovascular Infections Thursday, October 3, 2019: 12:15 PM Background. Staphylococcus aureus bacteremia (SAB) is associated with high morbidity and mortality rates. Data on epidemiology and outcomes of SAB in children is not as well described as in adults. The primary objective of this study was to describe clinical and microbiological cure rates of SAB in hospitalized children. Secondary objectives included time to clinical and microbiological cure, mortality, proportions of methicillin-sensitive and resistant SA (MSSA, MRSA) bacteremia, and antibiotic usage pattern.
Methods. This was an electronic chart abstraction conducted at a community hospital in the South Bronx, NY, of all pediatric cases of SAB (<21 years of age) from January 1, 2010 to March 30, 2017. Demographic, clinical and microbiological data along with risk factors for bacteremia were collected. Clinical cure was defined as resolution of acute symptoms and signs of SAB and microbiological cure was defined as documentation of first negative blood culture after initiation of treatment. Standard definitions were used for hospital-acquired (HA) and community-acquired (CA) isolates of SA.
Results. Of 41 patients, neonates comprised 12%, 1-to 23-month-old infants 56% and 2-to 17-year-olds 31%. Overall, 76% of patients had bacteremia due to MSSA, and 24% MRSA. MRSA was isolated in 37% of HA SAB compared with 14% of CA SAB (P = 0.15). The two highest risk factors identified for SAB were peripherally inserted central catheters lines (PICC, 29%) and skin and soft-tissue infections (22%). SAB in the neonatal period was associated with PICC lines when compared with children outside the neonatal period (80% vs. 22%, P = 0.02). Using available data, clinical and microbiological cure rates were similar at 73%. The median time to clinical cure was 5 days (interquartile range [IQR] 2-10) and to microbiological cure, 2 days (IQR 1-4). A 2-month-old infant died (mortality 2.4%). Initial antibiotic selection was vancomycin (39%), clindamycin (39%), and nafcillin (7%). The proportion of SA resistant to clindamycin was 22%.
Conclusion. Pediatric SAB was uncommon in this community hospital experience over 7 years and is associated with PICC lines in neonates. MSSA was more prevalent than MRSA. Initial antibiotic selection had anti-staphylococcal coverage in 85% of cases, while clindamycin resistance occurred in 22% of SA isolates.
